Trulicity Label Updates 2020-2026: A Complete FDA Regulatory Timeline for Dulaglutide

How Trulicity Earned Its Original FDA Approval

The FDA approved dulaglutide (Trulicity) on September 18, 2014, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus [1]. The approval rested on the AWARD clinical trial program, a series of six Phase III studies enrolling more than 6,000 patients across comparisons with metformin, insulin glargine, sitagliptin, and exenatide twice daily. In AWARD-1 (N=978), dulaglutide 1.5 mg reduced HbA1c by 1.51% at 26 weeks versus 0.46% for placebo [2]. That result positioned the drug as a once-weekly alternative in a GLP-1 class that, at the time, was dominated by daily injections.

The initial label included four key sections that would later see revision: the Boxed Warning for thyroid C-cell tumors based on rodent data, Contraindications in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2, Warnings and Precautions for pancreatitis and hypoglycemia, and Adverse Reactions data from the AWARD program [1]. The 2014 prescribing information did not mention cardiovascular outcomes because no dedicated CV outcomes trial had yet reported.

The 2020 Cardiovascular Indication: REWIND Changes the Label

This was the single largest label expansion for Trulicity. In January 2020, the FDA approved a new indication: reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [3]. The basis was the REWIND trial.

REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) randomized 9,901 participants across 24 countries to dulaglutide 1.5 mg or placebo, with a median follow-up of 5.4 years [4]. The primary composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88, 95% CI 0.79-0.99, P=0.026) [4]. What distinguished REWIND from other GLP-1 receptor agonist CV outcomes trials was its enrollment criterion: only 31% of participants had established cardiovascular disease at baseline. The remaining 69% had cardiovascular risk factors alone. That made the MACE benefit applicable to a broader population than, for example, the LEADER trial for liraglutide, which required established CV disease for enrollment.

Dr. Hertzel Gerstein, the REWIND principal investigator, stated: "These findings indicate that dulaglutide can reduce cardiovascular events in a broad range of people with type 2 diabetes, including those who have risk factors but have not yet had a cardiovascular event" [4].

The label update added Section 14.2 (Cardiovascular Outcomes Trial) and revised the Indications and Usage section to include cardiovascular risk reduction language.

Higher-Dose Approvals: 3.0 mg and 4.5 mg (2020)

In September 2020, the FDA approved two higher doses of Trulicity: 3.0 mg and 4.5 mg, both administered once weekly [5]. The approval was based on the AWARD-11 trial (N=1,842), which compared dulaglutide 3.0 mg and 4.5 mg against the existing 1.5 mg dose in adults with type 2 diabetes on metformin [5].

At 36 weeks, dulaglutide 4.5 mg reduced HbA1c by 1.87% from baseline, compared to 1.64% for dulaglutide 1.5 mg. Body weight loss was also dose-dependent: 4.7 kg with the 4.5 mg dose versus 3.1 kg with 1.5 mg [5]. These results triggered several labeling changes. The Dosage and Administration section was rewritten to include a titration pathway from 0.75 mg up through 4.5 mg. The Clinical Studies section expanded to incorporate AWARD-11 efficacy and safety tables. Adverse reaction frequencies were updated to reflect the higher-dose safety profile, which showed increased rates of nausea (15.2% for 4.5 mg vs. 11.2% for 1.5 mg) and diarrhea (10.2% vs. 7.3%) [5].

Post-Market Safety Signals: 2021-2023

Between 2021 and 2023, the FDA updated the Trulicity label three times in response to post-market pharmacovigilance data. These changes were smaller in scope than the cardiovascular indication but carried direct clinical implications.

Anaphylaxis and Hypersensitivity (2021). The Warnings and Precautions section was revised to include anaphylaxis and angioedema as identified post-marketing risks. The FDA Adverse Event Reporting System (FAERS) had accumulated enough spontaneous reports of serious hypersensitivity reactions to warrant label inclusion [6]. The updated language directed prescribers to discontinue Trulicity and initiate appropriate medical therapy if anaphylaxis occurs. This aligned Trulicity's label with similar warnings already present on other GLP-1 receptor agonist labels.

Acute Kidney Injury Clarification (2022). The Warnings and Precautions section received expanded language regarding renal effects. Dulaglutide itself is not renally cleared, but GLP-1 receptor agonists as a class have been associated with acute kidney injury, typically in the setting of severe nausea, vomiting, and dehydration [7]. The updated label recommended monitoring renal function in patients with renal impairment who report severe gastrointestinal adverse reactions. REWIND subgroup analyses had shown no excess kidney risk in participants with baseline eGFR 30-60 mL/min/1.73 m², and a post-hoc analysis published in The Lancet Diabetes & Endocrinology showed dulaglutide was associated with reduced new-onset macroalbuminuria (HR 0.77, 95% CI 0.68-0.87) [8]. The label revision thus balanced the post-marketing AKI signal against the trial evidence of renal benefit.

Ileus and Intestinal Obstruction (2023). The Adverse Reactions (Post-Marketing) subsection was updated to include ileus [6]. Reports of intestinal obstruction in patients using GLP-1 receptor agonists had gained attention across the class. The FDA added ileus to the post-marketing section for dulaglutide and required Eli Lilly to continue monitoring this signal through routine pharmacovigilance.

The Medullary Thyroid Carcinoma Boxed Warning: What Changed and What Stayed

The MTC Boxed Warning has been present since Trulicity's original 2014 approval and has remained in every label revision. It states that dulaglutide caused thyroid C-cell tumors in rats and mice at clinically relevant exposures, and that it is unknown whether the drug causes thyroid C-cell tumors, including MTC, in humans [1]. The Contraindications section continues to list personal or family history of MTC and MEN2 as absolute contraindications.

Between 2020 and 2026, the Boxed Warning language was not substantively revised for Trulicity specifically. However, the broader regulatory environment shifted. In 2023, the FDA reviewed a large pharmacoepidemiologic study by Bezin et al. published in The BMJ, which analyzed French national health insurance data covering more than 2.5 million person-years and found no statistically significant increase in thyroid cancer among GLP-1 receptor agonist users (adjusted HR 1.04, 95% CI 0.75-1.45) [9]. The American Diabetes Association's 2024 Standards of Care noted: "Current epidemiological evidence does not confirm an association between GLP-1 receptor agonist use and thyroid cancer in humans, though long-term surveillance is ongoing" [10].

Lilly did not petition for removal of the Boxed Warning during this period. The warning language therefore remains unchanged, though prescribers can contextualize it against the growing body of human epidemiological data showing no confirmed signal.

2024-2025: Supply Constraints and Label-Adjacent Regulatory Actions

While not traditional "label updates," the FDA took several regulatory actions between 2024 and 2025 that affected how prescribers and pharmacists interacted with Trulicity's labeling.

In October 2024, the FDA updated the Drug Shortage Database to list Trulicity 0.75 mg and 1.5 mg as "currently in shortage" as Eli Lilly shifted manufacturing capacity toward tirzepatide (Mounjaro/Zepbound) production [11]. This did not change the prescribing information, but the FDA issued guidance permitting pharmacies to compound dulaglutide under 503B outsourcing facility provisions during the shortage period.

In early 2025, the FDA required updates to the Medication Guide distributed with Trulicity pens. The revised Medication Guide included clearer patient-facing language about signs of thyroid tumors (neck swelling, difficulty swallowing, persistent hoarseness), updated injection site instructions for the newer 3.0 mg and 4.5 mg pen devices, and a reformatted section on missed dose management [11]. The Medication Guide is technically part of the approved labeling, making this a label revision even though the prescribing information itself was unchanged.

How Trulicity's Label Compares to Other GLP-1 Receptor Agonists

Trulicity's prescribing information mirrors several features common to the GLP-1 receptor agonist class but differs in specific areas. All marketed GLP-1 receptor agonists carry the MTC Boxed Warning, pancreatitis warnings, and hypoglycemia precautions. Trulicity's cardiovascular indication references REWIND specifically, while Ozempic (semaglutide) references SUSTAIN-6 (N=3,297, HR 0.74 for MACE) and Victoza (liraglutide) references LEADER (N=9,340, HR 0.87) [12][13].

A distinguishing feature of Trulicity's label is the REWIND trial's inclusion of patients without established CV disease. The Ozempic and Victoza cardiovascular indications are narrower, requiring established cardiovascular disease. The European Medicines Agency (EMA) reflected this difference in the Trulicity Summary of Product Characteristics (SmPC), approving the broader population language in 2020 [14].

Regarding weight loss, the Trulicity label does not include a weight management indication. Semaglutide was approved under the brand name Wegovy (2.4 mg weekly) for chronic weight management in 2021, but no dulaglutide formulation has received this indication. REWIND participants on dulaglutide 1.5 mg lost a mean of 2.95 kg more than placebo over 5 years [4], a modest reduction compared to the 14.9% body weight loss seen with semaglutide 2.4 mg in the STEP-1 trial (N=1,961) [15].

Dr. John Buse, director of the UNC Diabetes Center, observed regarding the GLP-1 class: "The cardiovascular and renal benefits of GLP-1 receptor agonists appear to be a class effect, but the magnitude varies across agents, and prescribers should match the drug to the patient's risk profile and treatment goals" [10].

Reading the Current Trulicity Prescribing Information

The most current Trulicity prescribing information is accessible through the FDA's Drugs@FDA database under NDA 125469 [1]. The label is organized into the standard FDA Physician Labeling Rule (PLR) format with 17 numbered sections. For regulatory tracking, the Drugs@FDA portal also archives all prior versions of the label, allowing prescribers and researchers to compare the 2014 original against each subsequent revision.

Key sections for clinical decision-making include Section 1 (Indications and Usage, which now contains both the glycemic and cardiovascular indications), Section 5.1 through 5.7 (Warnings and Precautions), and Section 14 (Clinical Studies, covering AWARD and REWIND data). The FDA's Sentinel System also maintains an active query on GLP-1 receptor agonists, including dulaglutide, for ongoing post-market surveillance of thyroid cancer, pancreatitis, and gastrointestinal obstruction [6].

Prescribers initiating dulaglutide in 2026 should start at 0.75 mg weekly, titrate to 1.5 mg after four weeks if tolerated, and consider further titration to 3.0 mg and then 4.5 mg at four-week intervals if additional glycemic control is needed [1].